Peripheral Vascular Scaffolds and Stents

Explore Abbott's Advanced Portfolio of Stents and Drug-Eluting Resorbable Scaffolds

Drug-Eluting Resorbable Scaffolds

Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

  • Now proven with 3-year data, Esprit™ BTK is the only device that does it all - treats vessel recoil and dissection, delivers everolimus drug to the lesion, and leaves nothing behind.1,2,3

Self-Expanding Stents

Supera™ Peripheral Stent System

  • Interwoven wires that mimic the dynamic twisting, bending, and shortening of the SFA and proximal popliteal4,5,6

Absolute Pro™ Peripheral Stent System

  • Tri-axial technology designed to ensure precise stent placement

Balloon-Expandable Stents

Omnilink Elite™ Peripheral Stent System

  • Cobalt chromium multi-link technology that allows for thin struts without sacrificing strength for flexibility and vessel conformability

Herculink Elite™ Peripheral Stent System

  • Excellent strength and deliverability to the renal arteries

Data on file at Abbott unless otherwise noted.

 

References

  1. Parikh, S., ct al. Long-Term Outcomes of the Esprit BTK Scaffold Versus Angioplasty in Infrapopliteal Chronic Limb -threatening lschemia: 3-Ycar Results from the LIFE-BTK Trial; TCT 2025.
  2. Excluding platinum markers. Data on File at Abbott.
  3. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold vcrsus Angioplasty for Infrapopliteal Artery Disease. N Eng J Med 2024; 390:9-19
  4. Chan et al. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease. Journal of Vascular Surgery; November 2015; 62:1201-9.
  5. Arena, A et al. Intravascular Ultrasound Evaluation of Intervowen Nitinol Stents at Implant; J Vascular Medicine & Surgery 2013; 1:13, 1-6
  6.  Garcia L, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic Supera stent, Catheter Cardiovasc Interv. 2017 Jun 1;89(7):1259-1267.

MAT-2116359 v3.0